


Chime Biologics and Waterstone team up to empower ADC development and manufacturing

13 November 2024 | News

Offering a comprehensive solution to the ADC developers for IND-enabling and clinical studies



China-based Chime Biologics, a leading global contract development and manufacturing organisation (CDMO) that enables its partners' success in biologics, and US-based Waterstone, a reliable partner for its worldwide customers through continuous improvement and innovation to ensure high quality and sustainable service, have announced a strategic partnership aimed at providing integrated services for Antibody-Drug Conjugate (ADC) industry worldwide.

Through this collaboration, Chime Biologics and Waterstone will offer a comprehensive solution to the ADC developers for IND-enabling and clinical studies.

Leveraging its CMC expertise in biologics, Chime Biologics will manage Antibody Intermediate, ADC Drug Substance and Drug Product process development and cGMP manufacturing. Waterstone will supply Linker-payload, a critical intermediate in the ADC manufacturing process.

Dr Faming Zhang, CEO of Waterstone commented, "Our partnership with Chime Biologics is a significant milestone for Waterstone. Their expertise in antibody drug development and GMP manufacturing will be instrumental as we expand into global markets and advance our assets."

Dr Jimmy Wei, President of Chime Biologics, added, "Currently, Chime Biologics has begun to undertake multiple ADC projects. This partnership will significantly advance our innovation and growth in the ADCfield. We look forward to exploring the boundless possibilities of ADC together with Waterstone."